サイケデリック・ドラッグの世界市場

サイケデリック・ドラッグの世界市場は2030年までに38億米ドルに達する見込み

2024年に19億米ドルと推定されるサイケデリック・ドラッグの世界市場は、2024年から2030年にかけてCAGR 11.6%で成長し、2030年には38億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるγ-ヒドロキシ酪酸は、CAGR13.8%を記録し、分析期間終了時には17億米ドルに達する見込みです。ケタミン分野の成長率は、分析期間中CAGR 9.0％と推定されます。

米国市場は5億3,000万米ドルと推定、中国はCAGR16.0％で成長予測

米国のサイケデリック・ドラッグ市場は、2024年には5億3,000万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億9,750万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは16.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.2%と10.4%と予測されています。欧州では、ドイツがCAGR約9.2%で成長すると予測されています。

世界のサイケデリック・ドラッグ市場- 主要動向と促進要因のまとめ

サイケデリック・ドラッグが医療の主流になりつつあるのはなぜか？

世界のサイケデリック・ドラッグ市場は、うつ病、不安障害、PTSD、依存症などの精神疾患の治療における治療効果が科学的に検証されつつあることを背景に、目覚ましい復活を遂げています。歴史的に反体制文化運動や娯楽的使用と結びついてきたシロシビン、LSD、MDMA、DMT、ケタミンなどのサイケデリックは、現在、精神科医療における可能性が厳しく研究されています。治療抵抗性うつ病（TRD）や心的外傷後ストレス障害（PTSD）の増加を特徴とするメンタルヘルス危機の高まりは、従来の抗うつ薬にとどまらない新たな治療法に対する緊急の必要性を生み出しています。臨床試験や調査研究により、サイケデリック医薬品は、管理された条件下で使用された場合、深遠な神経可塑性を誘発し、従来の医薬品ではしばしば達成できなかったような長期的な心理的治癒を促進することが実証されています。FDAがシロシビンやMDMAを用いた治療法に「画期的治療法」の指定を与えるなど、規制のスタンスが変化したことで、この分野への関心がさらに高まっています。大手製薬会社やバイオテクノロジー新興企業がこの分野に参入するにつれて、サイケデリック・ドラッグ市場は、より構造化され、臨床的に検証され、広く受け入れられる治療モデルへと移行し、これらの物質を縁の下の力持ちから主流の医療応用へと導いています。

調査と規制の進化はどのように市場拡大に拍車をかけているのか？

規制の開発と科学の進歩は、サイケデリック・ドラッグの商業化において重要な役割を果たしています。FDA（米国食品医薬品局）がサイケデリックの潜在的な治療効果を認めたことで、医薬品の承認が迅速化され、企業は研究開発を迅速に進めることができるようになりました。これと並行して、カナダ、オーストラリア、欧州の一部の国々は、医療用としての使用を受け入れるための政策変更を検討し始め、米国のいくつかの州は、治療用途のためにサイケデリックを非犯罪化または合法化しています。サイケデリック補助療法の有効性を支持する臨床的証拠が増えつつあることから、ベンチャーキャピタル企業、製薬大手、精神医療団体などが、シロシビンに基づく抗うつ薬、MDMA補助精神療法、ケタミン点滴などの研究に資金を提供し、多額の投資を集めています。研究機関やバイオテクノロジー企業は、サイケデリックな化合物を従来の医療の枠組みに組み込めるよう、製剤の最適化、送達メカニズムの改善、安全性プロファイルの強化に注力しています。さらに、デジタル治療薬とAI主導のメンタルヘルス・プラットフォームの拡大は、サイケデリック療法を補完し、ガイド付きの治療体験とセッション後のサポートを提供すると予想されます。エビデンスに基づく治療プロトコールと医師主導の管理モデルへのシフトは、メンタルヘルス治療の展望における真剣な競争相手として、サイケデリック・ドラッグが正当性を獲得するのに役立っています。

商業化戦略と投資動向はどのように業界を形成しているのか？

サイケデリック・ドラッグの商業化は、製薬会社やメンタルヘルスクリニックが広く採用されるための構造化されたフレームワークを開発するにつれ、勢いを増しています。業界における最も大きな変化の一つは、患者が医学的監視の下で管理された治療セッションを受ける、サイケデリック支援療法クリニックの設立です。サイケデリック研究を専門とする新興企業の増加により、これらの化合物の治療可能性を高めるための、新規製剤、微量投与戦略、徐放性バージョンの開発が進んでいます。企業はまた、天然に存在するサイケデリックの合成誘導体も研究しており、臨床効果を最大限に高めながら副作用を最小限に抑えることを目指しています。市場の急成長は投資家の大きな関心を集め、いくつかのサイケデリック・バイオテクノロジー企業が株式を公開し、大規模な臨床試験に資金を調達しています。さらに、学術機関、メンタルヘルス関連団体、製薬会社の協力により、FDAやEMAの承認に向けたパイプラインが加速しており、サイケデリック療法は市場での入手に近づいています。代替精神保健治療への需要が高まるにつれ、従来の製薬企業も買収や戦略的提携を通じてこの分野に参入し、この分野の拡大をさらに後押ししています。世界のメンタルヘルス支出の増加が予測される中、サイケデリック薬物療法のビジネスモデルは、保険償還モデルや政府が支援するメンタルヘルス・イニシアチブを取り入れながら進化していくと予想されます。

サイケデリック・ドラッグ市場の主な成長促進要因は？

世界のサイケデリック・ドラッグ市場の成長は、精神疾患の有病率の増加、代替療法の受容率の上昇、サイケデリック支援治療を支持する規制シフトなど、いくつかの要因によってもたらされます。従来の抗うつ薬には大きな限界があり、治療抵抗性うつ病の症例が増加していることから、新たな治療オプションに対する需要が高まっており、サイケデリックが実行可能な代替療法として位置づけられています。神経科学と精神薬理学の進歩により、精神薬が脳機能にどのような影響を与えるかについての理解が深まり、医療専門家や研究者の間で信頼が高まっています。精神衛生団体や影響力のある人々からの支持と相まって、精神薬の非人間性が高まっていることも、市場の拡大に一役買っています。シロシビン、MDMA、ケタミンをメンタルヘルスに応用することを評価する臨床試験の数が増えていることも、この分野への機関投資の拡大に寄与しています。サイケデリック・ウェルネス・リトリートの増加、メンタルヘルス支援のデジタル統合、サイケデリック支援治療を専門とする治療クリニックの拡大は、市場の裾野をさらに広げています。さらに、医薬品規制がサイケデリック医薬品に対応するように進化するにつれて、大規模な生産と商業化の取り組みが加速すると予想されます。個別化された治療プロトコル、AIを活用した患者モニタリング、遠隔医療支援システムの統合は、サイケデリック療法のアクセシビリティと有効性を高め、長期的な市場成長を確実なものにすると思われます。

セグメント

薬剤タイプ（ガンマヒドロキシ酪酸、ケタミン、シロシビン、リゼルギン酸ジエチルアミド、その他）、流通チャネル（病院薬局、小売薬局、その他の流通チャネル）、用途（治療抵抗性うつ病、アヘン中毒、心的外傷後ストレス障害、ナルコレプシー、パニック障害、その他）

調査対象企業の例

• Atai Life Sciences
• Beckley Psytech
• Bexson Biomedical
• Biomind Labs
• Bright Minds Biosciences
• CaaMTech
• Compass Pathways
• Cybin
• Delix Therapeutics
• Eleusis
• Entheon Biomedical
• Enveric Biosciences
• Field Trip Health
• GH Research
• Gilgamesh Pharmaceuticals
• Havn Life Sciences
• Jazz Pharmaceuticals
• Johnson & Johnson
• Lykos Therapeutics
• Mind Medicine（MindMed）

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Psychedelic Drugs Market to Reach US$3.8 Billion by 2030

The global market for Psychedelic Drugs estimated at US$1.9 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 11.6% over the analysis period 2024-2030. Gamma Hydroxybutyric Acid, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Ketamine segment is estimated at 9.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$530.0 Million While China is Forecast to Grow at 16.0% CAGR

The Psychedelic Drugs market in the U.S. is estimated at US$530.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$797.5 Million by the year 2030 trailing a CAGR of 16.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 10.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Global Psychedelic Drugs Market - Key Trends & Drivers Summarized

Why Are Psychedelic Drugs Gaining Mainstream Acceptance in Medicine?

The global psychedelic drugs market has witnessed a remarkable resurgence, driven by increasing scientific validation of their therapeutic benefits in treating mental health disorders such as depression, anxiety, PTSD, and addiction. Historically associated with countercultural movements and recreational use, psychedelics such as psilocybin, LSD, MDMA, DMT, and ketamine are now being rigorously studied for their potential in psychiatric care. The growing mental health crisis, characterized by rising cases of treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), has created an urgent need for novel treatment modalities beyond conventional antidepressants. Clinical trials and research studies have demonstrated that psychedelics, when used under controlled conditions, can induce profound neuroplasticity, promoting long-term psychological healing in a way that traditional pharmaceuticals often fail to achieve. The shift in regulatory stances, with the FDA granting "breakthrough therapy" designations to psilocybin and MDMA-based treatments, has further accelerated interest in this field. As major pharmaceutical companies and biotech startups enter the space, the psychedelic drugs market is moving toward a more structured, clinically validated, and widely accepted therapeutic model, bringing these substances from the fringes into mainstream medical applications.

How Is Research and Regulatory Evolution Fueling Market Expansion?

Regulatory developments and scientific advancements are playing a crucial role in the commercialization of psychedelic drugs. The FDA’s recognition of the potential therapeutic benefits of psychedelics has led to expedited pathways for drug approval, enabling companies to fast-track research and development efforts. In parallel, countries such as Canada, Australia, and parts of Europe have begun exploring policy changes to accommodate medical use, while several U.S. states have decriminalized or legalized psychedelics for therapeutic applications. The growing body of clinical evidence supporting the efficacy of psychedelic-assisted therapy has attracted significant investment, with venture capital firms, pharmaceutical giants, and mental health organizations funding research into psilocybin-based antidepressants, MDMA-assisted psychotherapy, and ketamine infusions. Research institutions and biotech firms are focusing on optimizing psychedelic formulations, improving delivery mechanisms, and enhancing safety profiles to ensure that these compounds can be integrated into conventional medical frameworks. Furthermore, the expansion of digital therapeutics and AI-driven mental health platforms is expected to complement psychedelic therapy, offering guided treatment experiences and post-session support. The shift toward evidence-based treatment protocols and physician-led administration models is helping psychedelic drugs gain legitimacy as serious contenders in the mental health treatment landscape.

How Are Commercialization Strategies and Investment Trends Reshaping the Industry?

The commercialization of psychedelic drugs is gaining momentum as pharmaceutical companies and mental health clinics develop structured frameworks for widespread adoption. One of the biggest shifts in the industry is the establishment of psychedelic-assisted therapy clinics, where patients undergo controlled therapeutic sessions under medical supervision. The increasing number of startups specializing in psychedelic research has led to the development of novel formulations, microdosing strategies, and extended-release versions of these compounds to enhance their therapeutic potential. Companies are also exploring synthetic derivatives of naturally occurring psychedelics, aiming to minimize side effects while maximizing clinical efficacy. The rapid growth of the market has drawn significant investor interest, with several psychedelic biotech firms going public and raising capital to fund large-scale clinical trials. Moreover, collaborations between academic institutions, mental health organizations, and pharmaceutical companies are accelerating the pipeline for FDA and EMA approvals, bringing psychedelic therapies closer to market availability. As the demand for alternative mental health treatments grows, traditional pharmaceutical players are also entering the space, either through acquisitions or strategic partnerships, further driving the sector’s expansion. With a projected increase in mental health spending worldwide, the business model for psychedelic drug therapy is expected to evolve, incorporating insurance reimbursement models and government-backed mental health initiatives.

What Are the Key Growth Drivers of the Psychedelic Drugs Market?

The growth in the global psychedelic drugs market is driven by several factors, including increasing prevalence of mental health disorders, rising acceptance of alternative therapies, and regulatory shifts favoring psychedelic-assisted treatment. The significant limitations of conventional antidepressants and the growing cases of treatment-resistant depression have intensified the demand for novel therapeutic options, positioning psychedelics as a viable alternative. Advances in neuroscience and psychopharmacology have provided a better understanding of how psychedelics impact brain function, fostering greater confidence among healthcare professionals and researchers. The increasing destigmatization of psychedelics, coupled with advocacy from mental health organizations and influencers, has also played a role in market expansion. The growing number of clinical trials evaluating psilocybin, MDMA, and ketamine for mental health applications has contributed to greater institutional investment in the field. The rise of psychedelic wellness retreats, digital integration of mental health support, and expansion of therapy clinics specializing in psychedelic-assisted treatments are further broadening the market’s reach. Additionally, as pharmaceutical regulations evolve to accommodate psychedelic medicine, large-scale production and commercialization efforts are expected to accelerate. The integration of personalized treatment protocols, AI-driven patient monitoring, and telemedicine support systems will likely enhance the accessibility and effectiveness of psychedelic therapy, ensuring long-term market growth.

SCOPE OF STUDY:

The report analyzes the Psychedelic Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels); Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Atai Life Sciences
• Beckley Psytech
• Bexson Biomedical
• Biomind Labs
• Bright Minds Biosciences
• CaaMTech
• Compass Pathways
• Cybin
• Delix Therapeutics
• Eleusis
• Entheon Biomedical
• Enveric Biosciences
• Field Trip Health
• GH Research
• Gilgamesh Pharmaceuticals
• Havn Life Sciences
• Jazz Pharmaceuticals
• Johnson & Johnson
• Lykos Therapeutics
• Mind Medicine (MindMed)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Psychedelic Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Mental Health Burden Throws the Spotlight on Psychedelic Therapies for Treatment-Resistant Disorders
  • Expansion of Clinical Trials for Depression, PTSD, and Anxiety Disorders Drives Legitimization of Psychedelic Drug Therapies
  • Growing Investment from Biotech and Pharma Companies Strengthens Business Case for Psychedelic Drug Development
  • Regulatory Breakthrough Designations and Fast-Track Approvals Propel Commercialization of Psychedelic Compounds
  • Emergence of Psilocybin, MDMA, and LSD as Novel Psychiatric Treatments Spurs Drug Pipeline Diversification
  • Integration of Psychedelic Therapy in Controlled Clinical Environments Drives Development of Holistic Care Models
  • Advancements in Neuroplasticity Research Accelerate Scientific Understanding of Psychedelic Mechanisms of Action
  • Shift Toward Personalized Psychiatry Supports Use of Psychedelics in Tailored Mental Health Interventions
  • Increased Acceptance of Psychedelic-Assisted Therapy Among Healthcare Providers Spurs Institutional Adoption
  • Strategic Collaborations Between Academic Institutions and Psychedelic Startups Enhance R&D Infrastructure
  • Expansion of Ketamine Clinics and Off-Label Use Creates Gateway for Broader Psychedelic Drug Adoption
  • Rise of Functional and Microdosing Applications Expands Consumer Interest Beyond Traditional Psychedelic Use Cases
  • Growing Public and Media Advocacy Drives Societal Reframing and Reduces Stigma Around Psychedelic Medicines
  • Development of Psychedelic-Inspired Non-Hallucinogenic Compounds Strengthens Safety and Scalability Prospects
  • Focus on Intellectual Property and Proprietary Delivery Technologies Accelerates Commercial Differentiation
  • Increased Venture Capital and Public Market Funding Fuels Growth of Psychedelic Drug Companies and Research Platforms
  • Progressive Legal Reforms and Decriminalization Initiatives Expand Access and Policy Support in Key Regional Markets
  • Regulatory and Ethical Considerations in Psychedelic Therapy Protocols Create Demand for Standardization and Governance
  • Integration of Digital Health Tools and Psychedelic Therapies Enhances Monitoring, Adherence, and Data Collection
  • Expansion of Psychedelic Research into Addiction, Eating Disorders, and Neurodegenerative Diseases Broadens Indication Base
  • Rising Consumer Interest in Consciousness Exploration and Wellness Experiences Generates Demand for Legal Psychedelic Retreats
  • Challenges in Clinical Trial Design, Blinding, and Placebo Response Create Opportunities for Methodological Innovation
  • Globalization of Psychedelic Research Consortia and Clinical Networks Drives Collaborative Advancements and Knowledge Sharing
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Psychedelic Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Psychedelic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Psychedelic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Psychedelic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Gamma Hydroxybutyric Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Gamma Hydroxybutyric Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Gamma Hydroxybutyric Acid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Ketamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Ketamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Ketamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Psilocybin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Psilocybin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Psilocybin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Lysergic Acid Diethylamide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Lysergic Acid Diethylamide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Lysergic Acid Diethylamide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Opiate Addiction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Opiate Addiction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Opiate Addiction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Post-Traumatic Stress Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Post-Traumatic Stress Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Narcolepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Narcolepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Narcolepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Panic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Panic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Panic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Treatment-Resistant Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Treatment-Resistant Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Treatment-Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• JAPAN
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• CHINA
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• EUROPE
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Psychedelic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Psychedelic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Psychedelic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• FRANCE
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 95: France Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• GERMANY
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 122: UK Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Psychedelic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Psychedelic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Psychedelic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• INDIA
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 179: India Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Psychedelic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Psychedelic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Psychedelic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Psychedelic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Psychedelic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Psychedelic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• AFRICA
  • Psychedelic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Psychedelic Drugs by Drug Type - Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Psychedelic Drugs by Drug Type - Percentage Breakdown of Value Sales for Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Psychedelic Drugs by Application - Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Psychedelic Drugs by Application - Percentage Breakdown of Value Sales for Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Other Applications and Treatment-Resistant Depression for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Psychedelic Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Psychedelic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION